Skip to main content

Zipalertinib

  • Clinical activity of zipalertinib with(out) combinations to support rationale for use in EGFR mut. NSCLC e.g. common and uncommon mutations
  • Clinical activity of zipalertinib with(out) combinations in broader patient group (with demonstrable rationale)
  • Novel treatment approaches for areas of unmet need including but not limited to brain metastasis or leptomeningeal disease.
  • Early stage, non-metastatic treatment including neoadjuvant “window of opportunity” trials utilizing novel (non-survival) endpoints.
  • Dosing studies with zipalertinib in specific subpopulations (i.e. brain metastasis)
  • Non-interventional biomarker studies (as an add on study)